Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.
Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.
“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.
“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”
This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.
The findings are published on line in the journal EBioMedicine, published by The Lancet.
Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.
The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.
“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.
“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.
The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.
Receive an email update when we add a new DUPUYTRENS DISEASE article.
The Latest on: Dupuytren’s disease
via Google News
The Latest on: Dupuytren’s disease
- Why Apprenticeships Could Hold The Key To The Next Wave Of Data Science Talent on December 18, 2018 at 8:52 am
At the minute, I am creating a Version.3 of a form to capture the data for measuring the spread of Dupuytren's disease, which causes a condition called Dupuytren's contracture, in which one or more fi... […]
- Hunter Dupuytren's disease research explores whether radiotherapy can be used to manage and prevent common hand condition on December 13, 2018 at 1:00 pm
IT IS a common condition that can cause “clawing” of the fingers, but a world-first clinical trial now underway at Lake Macquarie hopes to find a better treatment for people with “viking disease”. Gen... […]
- New hope for patients with incurable and disabling hand condition, Dupuytren's disease on July 6, 2018 at 8:09 am
Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that i... […]
- Can rock climbing lead to Dupuytren’s disease? on July 2, 2018 at 1:22 pm
Objectives: To determine if rock climbing is a significant factor in the development of Dupuytren’s disease in men, and, if so, what is the most likely related factor. Methods: Questionnaires were dis... […]
- Dupuytren's Contracture on March 15, 2018 at 12:25 pm
Dupuytren’s contracture is a fairly rare disease that slowly progresses over years and even decades. Usually in the 40’s to 60’s is when you would first notice the symptoms. Dupuytren’s is more common ... […]
- List of Hand & Wrist Diseases on September 29, 2017 at 5:00 pm
DeQuervain’s disease is treated by splinting the area, stretching the tendons, rest, cortisone injections and possible surgery. Dupuytren’s disease is the abnormal thickening of the tissue beneath the ... […]
- Low second to fourth digit ratio in Dupuytren disease on July 25, 2017 at 5:00 pm
Abstract: The ratio of the lengths of the second and fourth digits (2D:4D) has been described as reflecting endogenous prenatal androgen exposure. In general, 2D:4D is lower in men than in women and h... […]
- NICE recommends Xiapex for NHS in England to treat Dupuytren’s contracture on July 2, 2017 at 9:45 pm
Swedish Orphan Biovitrum AB (Sobi) announced that for the first time people in England with the disabling hand condition Dupuytren’s disease will have access to Xiapex (collagenase clostridium histoly... […]
- Xiapex® gets recommendation to be made available on National Health Service in England on June 30, 2017 at 2:00 am
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that for the first time people in England with the disabling hand condition Dupuytren’s disease will have access to Xiapex® (collagenase clos... […]
via Bing News